European Journal of Clinical Pharmacology

, Volume 69, Issue 7, pp 1401–1409 | Cite as

Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers

  • Christina L. Aquilante
  • Michael F. Wempe
  • Maha S. Sidhom
  • Lisa A. Kosmiski
  • Julie A. Predhomme



The objectives of this study were to determine if ABCB1 polymorphisms are associated with interindividual variability in sitagliptin pharmacokinetics and if atorvastatin alters the pharmacokinetic disposition of sitagliptin in healthy volunteers.


In this open-label, randomized, two-phase crossover study, healthy volunteers were prospectively stratified according to ABCB1 1236/2677/3435 diplotype (n = 9, CGC/CGC; n = 10, CGC/TTT; n = 10, TTT/TTT). In one phase, participants received a single 100 mg dose of sitagliptin; in the other phase, participants received 40 mg of atorvastatin for 5 days, with a single 100 mg dose of sitagliptin administered on day 5. A 24-h pharmacokinetic study followed each sitagliptin dose, and the study phases were separated by a 14-day washout period.


Sitagliptin pharmacokinetic parameters did not differ significantly between ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotype groups during the monotherapy phase. Atorvastatin administration did not significantly affect sitagliptin pharmacokinetics, with geometric mean ratios (90 % confidence intervals) for sitagliptin maximum plasma concentration, plasma concentration–time curve from zero to infinity, renal clearance, and fraction of sitagliptin excreted unchanged in the urine of 0.93 (0.86–1.01), 0.96 (0.91–1.01), 1.02 (0.93–1.12), and 0.98 (0.90–1.06), respectively.


ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotypes did not influence sitagliptin pharmacokinetics in healthy volunteers. Furthermore, atorvastatin had no effect on the pharmacokinetics of sitagliptin in the setting of ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotypes.


Sitagliptin Atorvastatin ABCB1 P-glycoprotein Pharmacogenetics Pharmacokinetics 



We would like to thank the study volunteers for their participation, and the nursing and administrative staff at the University of Colorado Clinical and Translational Research Center for assisting with the conduct of the study. The study was funded by National Institutes of Health (NIH) grants R03 DK084089 (to CLA) and UL1 TR000154 (to University of Colorado). The research utilized the services of the Medicinal Chemistry Core facility (MFW) housed within the Department of Pharmaceutical Sciences at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. The Medicinal Chemistry Core facility receives funding via the Colorado Clinical and Translational Sciences Institute (CCTSI), which is supported in part by CTSA grant UL1TR000154 from NIH/NCRR. The contents of this article are the authors’ sole responsibility and do not necessarily represent official NIH views.

Supplementary material

228_2013_1475_MOESM1_ESM.docx (16 kb)
ESM 1 (DOCX 15 kb)


  1. 1.
    Herman GA, Stein PP, Thornberry NA, Wagner JA (2007) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 81:761–767PubMedCrossRefGoogle Scholar
  2. 2.
    Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675–688PubMedCrossRefGoogle Scholar
  3. 3.
    Merck Sharp & Dohme Corp (2012) Januvia (sitagliptin) prescribing information. Merck & Co. Inc, Whitehouse Station, NJ. Available at:
  4. 4.
    Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA (2007) Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533–538PubMedCrossRefGoogle Scholar
  5. 5.
    Scheen AJ (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12:648–658PubMedCrossRefGoogle Scholar
  6. 6.
    Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R (2007) Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321:673–683PubMedCrossRefGoogle Scholar
  7. 7.
    Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman G (2007) Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 47:165–174PubMedCrossRefGoogle Scholar
  8. 8.
    Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261–283PubMedCrossRefGoogle Scholar
  9. 9.
    Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 21:152–161PubMedCrossRefGoogle Scholar
  10. 10.
    Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528PubMedCrossRefGoogle Scholar
  11. 11.
    Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRefGoogle Scholar
  12. 12.
    Chinn LW, Kroetz DL (2007) ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 81:265–269PubMedCrossRefGoogle Scholar
  13. 13.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 285:2486−2497CrossRefGoogle Scholar
  14. 14.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44:720–732PubMedCrossRefGoogle Scholar
  15. 15.
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRefGoogle Scholar
  16. 16.
    Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care 28:1151–1157PubMedCrossRefGoogle Scholar
  17. 17.
    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29:1220–1226PubMedCrossRefGoogle Scholar
  18. 18.
    Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117–125PubMedCrossRefGoogle Scholar
  19. 19.
    Scheen AJ (2012) Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 8:745–758PubMedCrossRefGoogle Scholar
  20. 20.
    Wu X, Whitfield LR, Stewart BH (2000) Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 17:209–215PubMedCrossRefGoogle Scholar
  21. 21.
    Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L (2000) Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40:91–98PubMedCrossRefGoogle Scholar
  22. 22.
    Wang E, Casciano CN, Clement RP, Johnson WW (2001) HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 18:800–806PubMedCrossRefGoogle Scholar
  23. 23.
    Bogman K, Peyer AK, Torok M, Kusters E, Drewe J (2001) HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132:1183–1192PubMedCrossRefGoogle Scholar
  24. 24.
    Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T (2004) Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1686–1691PubMedCrossRefGoogle Scholar
  25. 25.
    Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA (2005) Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537–546PubMedCrossRefGoogle Scholar
  26. 26.
    Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K (2006) Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 23:506–512PubMedCrossRefGoogle Scholar
  27. 27.
    Holtzman CW, Wiggins BS, Spinler SA (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26:1601–1607PubMedCrossRefGoogle Scholar
  28. 28.
    Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP (2008) Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 48:1323–1338PubMedCrossRefGoogle Scholar
  29. 29.
    Andrisin TE, Humma LM, Johnson JA (2002) Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22:954–960PubMedCrossRefGoogle Scholar
  30. 30.
    U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry (2012) Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Available at: Accessed 13 Aug 2012
  31. 31.
    Leschziner GD, Andrew T, Pirmohamed M, Johnson MR (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7:154–179PubMedCrossRefGoogle Scholar
  32. 32.
    Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478PubMedCrossRefGoogle Scholar
  33. 33.
    Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159–171PubMedCrossRefGoogle Scholar
  34. 34.
    Choi DH, Shin WG, Choi JS (2008) Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol 64:445–449PubMedCrossRefGoogle Scholar
  35. 35.
    Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425–461PubMedCrossRefGoogle Scholar
  36. 36.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28:55–72PubMedCrossRefGoogle Scholar
  37. 37.
    Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ (2010) Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 10:7PubMedCrossRefGoogle Scholar
  38. 38.
    Scheen AJ (2010) Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug–drug interactions. Clin Pharmacokinet 49:573–588PubMedCrossRefGoogle Scholar
  39. 39.
    Karim A, Fleck P, Harris S, Munsaka M, Weiss M, Mekki Q (2008) Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects. Clin Pharmacol Ther 83:S14CrossRefGoogle Scholar
  40. 40.
    Ayalasomayajula SP, Dole K, He YL, Ligueros-Saylan M, Wang Y, Campestrini J, Humbert H, Sunkara G (2007) Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 23:2913–2920PubMedCrossRefGoogle Scholar
  41. 41.
    Patel CG, Li L, Girgis S, Kornhauser DM, Frevert EU, Boulton DW (2011) Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 3:13–25PubMedGoogle Scholar
  42. 42.
    Kao DP, Kohrt HE, Kugler J (2008) Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 25:1229–1230PubMedCrossRefGoogle Scholar
  43. 43.
    DiGregorio RV, Pasikhova Y (2009) Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy 29:352–356PubMedCrossRefGoogle Scholar
  44. 44.
    Bhome R, Penn H (2012) Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med 29:693–694PubMedCrossRefGoogle Scholar
  45. 45.
    Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M (2008) ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84:457–461PubMedCrossRefGoogle Scholar
  46. 46.
    Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY (2010) Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 48:36–45PubMedGoogle Scholar
  47. 47.
    Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–181PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Christina L. Aquilante
    • 1
  • Michael F. Wempe
    • 1
  • Maha S. Sidhom
    • 1
  • Lisa A. Kosmiski
    • 2
  • Julie A. Predhomme
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesAuroraUSA
  2. 2.Division of Endocrinology, Diabetes, and MetabolismUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations